Evidence map›Paper›PMID 37908308›Full record

ReviewPsoriasis (Auckland, N.Z.)2023

The Skin Microbiome and Its Role in Psoriasis: A Review.

Valentina Celoria, Francois Rosset, Valentina Pala, Paolo Dapavo, Simone Ribero, Pietro Quaglino, Luca Mastorino

Registry-linked trialOpen access · goldAbstract readReview
In one paragraph

Review in Psoriasis (Auckland, N.Z.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07169019 (Gut Microbiome Changes and Clinical Impact Induced by Treatment of Newly Diagnosed Psoriasis Patients With Probiotics and Methotrexate), which is not on this map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
14.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07169019 early_phase1recruitingnot on this mapstarted 2025, after this paper: background citation

Gut Microbiome Changes and Clinical Impact Induced by Treatment of Newly Diagnosed Psoriasis Patients With Probiotics and Methotrexate: a Pilot Study

TypeinterventionalSponsorAlexandria UniversityRan2025 to 2026Enrolled24ConditionsPsoriasis (PsO)ArmsProbiotics and methotrexate, Methotrexate
3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 52 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Antibiotics (Basel, Switzerland) · 2024
    Review
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Valentina Celoria *Dermatologic Clinic, Department of Medical Sciences, University of Turin, Turin, Italy.
Francois Rosset *Dermatologic Clinic, Department of Medical Sciences, University of Turin, Turin, Italy.ORCID 0000-0002-1655-0395
Valentina PalaDermatologic Clinic, Department of Medical Sciences, University of Turin, Turin, Italy.
Paolo DapavoDermatologic Clinic, Department of Medical Sciences, University of Turin, Turin, Italy.
Simone RiberoDermatologic Clinic, Department of Medical Sciences, University of Turin, Turin, Italy.
Pietro QuaglinoDermatologic Clinic, Department of Medical Sciences, University of Turin, Turin, Italy.
Luca MastorinoDermatologic Clinic, Department of Medical Sciences, University of Turin, Turin, Italy.ORCID 0000-0001-7386-3219
University of Turin · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The skin microbiome is made of various microorganisms, most of which have the function of protecting individuals from harmful pathogens, and they are involved in innate and adaptive immune responses. The skin acts as a physical and immunological barrier against external stimuli, including pathogens and physical damage. Changes in the composition of the skin microbiome can trigger inflammatory processes leading to inflammatory skin diseases in susceptible individuals. Psoriasis (PsO) is a chronic inflammatory disease with a multifactorial etiology, where breakdown of immune tolerance to cutaneous microorganisms is implicated in its pathogenesis. Dysregulation of the microbiome due to genetic and environmental factors plays a significant role in the development of psoriatic disease. Dermatologic conditions such as atopic dermatitis, acne, psoriasis, and rosacea have been associated with intestinal dysbiosis. The skin microbiota composition is crucial for the development of appropriate immune responses, and alterations in the skin microbiome can contribute to changes in physiology and susceptibility to skin diseases or inflammatory conditions. Understanding the microbial settlement of the skin and the network of interactions that occur throughout life is essential for comprehending the pathogenesis of skin diseases and developing innovative treatments. With this article we tried to explore the relationship between the human microbiome and psoriatic disease, shedding light on the functions of the microbiome and the inflammatory disease processes to identify additional therapeutic targets. This review aims to highlight the relationship between skin and gut microbiome functions and inflammatory processes in skin psoriasis and psoriatic arthritis (PsA). The goal is to facilitate future studies on the skin microbiome to identify potential novel therapies for patients with psoriatic disease.

Indexed as

gut microbiomemolecular precision medicinesnew therapiesnext generation treatmentspsoriasisskin microbiome

Identifiers

PMID37908308
PMCPMC10614657
OpenAlexW4388141100

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.